Detalhe da pesquisa
1.
Withholding the Introduction of Anti-Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wild-Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study).
Oncologist
; 25(2): e266-e275, 2020 02.
Artigo
Inglês
| MEDLINE | ID: mdl-32043796